What did @theflywheeleffect actually say?
In short: they injected what they called "reda" (retatrutide) and MT-2 (melanotan II) together on their first night, reported nausea that resolved in about 20 minutes, and then claimed they noticed belly fat loss and facial changes within 24 hours. They also went roughly 24 hours without feeling hungry. The video is framed as a personal documentation series, not medical guidance, but the claims embedded in it are specific enough to warrant scrutiny.
The creator said they "pinned them all back to back to back" after reconstituting the compounds themselves. They attributed the nausea to MT-2 specifically, and called the appetite suppression effect immediate and significant. The phrase "it's already working" after one injection is the claim that deserves the most attention here.
Does the science back this up?
The appetite suppression claim after a single retatrutide injection is the most plausible part of this video. The fat loss and facial change claims after 24 hours are not supported by any existing pharmacokinetic data.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. In the Phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine), participants lost an average of 17.5% body weight over 24 weeks. Appetite suppression does appear early in GLP-1 receptor agonist use, consistent with delayed gastric emptying and central satiety signaling. So going nearly 24 hours without hunger after a first injection is biologically plausible, though individual responses vary significantly.
Losing visible belly fat or noticing facial changes in under 24 hours is not biologically plausible. Adipose tissue reduction requires sustained caloric deficit over days to weeks minimum. What the creator likely experienced is reduced bloating from eating less, not actual fat loss.
MT-2's nausea profile is well-documented. Wessells et al. (1998, Journal of Urology) noted facial flushing and nausea as common acute side effects, consistent with what the creator described.
What did they get wrong (or right)?
They got the nausea attribution roughly right. MT-2 is a melanocortin receptor agonist and nausea is one of its most consistently reported acute side effects. Credit where it is due.
They got the appetite suppression observation directionally right for GLP-1 mechanisms, though calling it dramatic after one pin overstates what one dose can confirm.
What they got wrong, plainly: "I already have noticed a huge difference" in fat loss after 24 hours is not a pharmacological effect. It is perception bias. Fat oxidation and redistribution do not operate on 24-hour timescales from a single injection. This is a common pattern in self-experiment content where expectation shapes reported experience.
What they also did not address is the risk profile of stacking two compounds with distinct and potentially compounding side effect profiles on day one, with no baseline established for either. Retatrutide is not FDA-approved and exists only in clinical trial or compounded form. MT-2 has no regulatory approval anywhere. Self-reconstituting and co-administering both without medical supervision raises real safety concerns that get zero airtime in this video.
What should you actually know?
Retatrutide is still in clinical development. It is not FDA-approved as of mid-2025. Any version being injected outside a clinical trial is a compounded or gray-market product, and quality control is not guaranteed. The Jastreboff 2023 trial used pharmaceutical-grade material under medical supervision with regular monitoring.
MT-2 is not approved by the FDA or any major regulatory body for any indication. It is sometimes used off-label for tanning and sexual dysfunction, but its safety profile at the doses people use in self-experimentation is not well characterized in long-term studies.
Stacking two unapproved compounds on day one, without baseline labs or medical oversight, is the kind of thing that makes adverse event reporting nearly impossible if something goes wrong. You have no idea which compound caused what.
The appetite suppression from GLP-1-based compounds is real and clinically meaningful, but it comes with documented risks including nausea, vomiting, gastroparesis-like symptoms, and in rare cases pancreatitis. Anyone considering these compounds should be doing so under the care of a licensed provider who can monitor for those outcomes, not following a TikTok series to inform their dosing schedule.